Data Intelligence And Biopharma's COVID-19 Responsibility - BioProcess

Thursday, April 9, 2020

For the past two months, the world outside of this industry has been laser-focused on its attempts to speed its way to COVID-19 vaccines and treatments. Dozens of biopharma firms large and small that have turned their development programs on their ears, reallocating huge resources to explore their molecules’ potential in the war on this pandemic.
By Susan Willman